NEW RESEARCH—5-year data from the TREAT EARLIER trial shows that a time-limited methotrexate intervention has different effects in patients with ACPA-positive and ACPA-negative arthralgia at increased risk for rheumatoid arthritis www.thelancet.com/journals/lan... #Medsky #Rheumsky

NEW RESEARCH—Secukinumab biosimilar BAT2306 versus reference secukinumab in patients with moderate-to-severe plaque psoriasis: a multicentre, double-blind, randomised, active-controlled, phase 3 trial www.thelancet.com/journals/lan... #Medsky #Rheumsky #Dermsky

NEW RESEARCH—Trends in autoimmune rheumatic disease diagnoses before and after the COVID-19 pandemic in England: a population-based cohort study using @OpenSAFELY bit.ly/4p6WELY Plus linked Comment by @jeffsparks.bsky.social bit.ly/446onmh

We are a world-leading #rheumatology journal, ranking:   #2 Journal Impact Factor (29·5)   #3 Scopus CiteScore (28·5)  Explore our high impact and global reach: hubs.li/Q04k_q2n0 #RheumSky

🥇 The Lancet is now ranked the world’s #1 general medical journal—in both Journal Impact Factor (109·0) and Scopus CiteScore (92·4). No other general medical journal comes close. Your next clinical breakthrough belongs here. Learn more ➡️ hubs.ly/Q04k-V2N0

NEW HEALTH POLICY—Aligning approaches to rheumatoid arthritis drug development: a comparison of FDA and EMA guidance www.thelancet.com/journals/lan... #Medsky #Rheumsky

Our July 2026 issue is live! Including clinical trials in cutaneous #lupus, #Sjogrens disease, and #RheumatoidArthritis, plus much more! thelancet.com/journals/lan... Cover by @emma-cheng.bsky.social #Medsky #Rheumsky

NEW Patient Voice—Beyond laboratory tests: when normal results aren’t the finish line—by Dana Guglielmo www.thelancet.com/journals/lan... #Medsky #Rheumsky

NEW COMMENT—Baricitinib and ruxolitinib use through the UK #HLH Network www.thelancet.com/journals/lan... #Medsky #Rheumsky #IDsky

📢Announcing @thelancetrheum.bsky.social Commission on reproductive health and family planning in immune-mediated long-term conditions: empowering special reproductive journeys Read all about it here ➡️https://bit.ly/4vrdHKt @lauraandreoli.bsky.social @karenschreiber.bsky.social

🥇 The first @thelancetrheum.bsky.social commission was born today! 🎯 Our vision: A future where people living with immune mediated long term conditions achieve sexual & reproductive wellbeing across their life course. @lauraandreoli.bsky.social @karenschreiber.bsky.social #LancetRheumCommission

NEW RESEARCH—The role of health literacy in clinical, treatment, and work-related outcomes in people with inflammatory #arthritis in England: a cross-sectional study bit.ly/4vntQk9 @drminidey.bsky.social And linked Comment bit.ly/4a6amrX #Medsky #Rheumsky

Attending #EULAR2026 in London next week? Anna Clark, Editor-in-Chief, invites you to reach out with enquiries. Explore our scope, reach & impact, commitment to publishing excellence, & more: hubs.li/Q03BLchR0 #Medsky #Rheumsky

Our June 2026 issue is live! Including research on genetics of #SystemicSclerosis, clinical criteria for #Still's disease, difficult-to-treat #RheumatoidArthritis, and time to #pregnancy in RA, plus much more! www.thelancet.com/journals/lan... Cover by @emma-cheng.bsky.social #Medsky #Rheumsky

NEW—Long-term treatment transition patterns after intensive treatment strategies in early psoriatic arthritis: insights from the GOLMePsA clinical trial www.thelancet.com/journals/lan... #Medsky #Rheumsky

NEW RESEARCH—Prevalence and determinants of sacroiliac joint bone marrow oedema in the general population in Germany: a population-based cross-sectional study www.thelancet.com/journals/lan... #Medsky #Rheumsky

NEW VIEWPOINT—When one joint matters: the monoarticular blind spot in inflammatory arthritis www.thelancet.com/journals/lan... #Medsky #Rheumsky

NEW RESEARCH—Efficacy and safety of enpatoran, a Toll-like receptor 7/8 inhibitor, in patients with skin manifestations of cutaneous lupus erythematosus or systemic lupus erythematosus: findings from Cohort A of a phase 2 trial bit.ly/42WYW5O Linked Comment bit.ly/4314gVL #WorldLupusDay #Rheumsky

NEW podcast episode 🎧 Acting Deputy Editor, Aisling O'Brien, talks to Dirk Foell about trends in paediatric rheumatology care across Europe Listen now wherever you get your podcasts! Apple: bit.ly/4tkAqXf Spotify: bit.ly/4ncXWUF Full Viewpoint: bit.ly/4eqGxp6 #Medsky #Rheumsky

NEW RESEARCH—Effectiveness and persistence of biological and targeted synthetic treatment in patients with rheumatoid arthritis and chronic kidney disease: a multicentre, prospective cohort study bit.ly/49mVODT #Medsky #Rheumsky

NEW RESEARCH—Sex-specific autosomal susceptibility loci in systemic sclerosis: a genome-wide association study bit.ly/3OHY4ys Plus, linked Comment bit.ly/4e8AvJK #Medsky #Rheumsky

Our May 2026 issue is live! Including research on #hyperuricaemia, #gout, zoster #vaccine, and #JIA, plus much more! www.thelancet.com/journals/lan... Cover by @emma-cheng.bsky.social #Medsky #Rheumsky

NEW RESEARCH—Associated lifestyle factors and comorbidities of difficult-to-treat rheumatoid arthritis: a systematic review and meta-analysis bit.ly/4tSOebX Plus linked Comment bit.ly/4cFTGIr #Medsky #Rheumsky

NEW—Detection of GLP-1 and DPP-4 in synovial fluid: implications for therapeutical strategies in arthritis bit.ly/4my0EUf #MedSky #RheumSky

NEW REVIEW—Glucocorticoid treatment in patients with inflammatory rheumatic diseases: current practice and open questions bit.ly/3PP9xwD

NEW podcast episode 🎧 As part of our theme issue on patient and public involvement in rheumatology, Aisling O'Brien talks to Jon Lampa about patient-reported outcomes from the NORD-STAR trial Listen on Apple bit.ly/4rYkOYD Spotify bit.ly/4cdG4oB Full Article bit.ly/411D48I #Medsky #Rheumsky

💥 KABOOM! Our #LupusGPT work is now published in @thelancetrheum.bsky.social‼️ 🏆 A big moment for LupusGPT, but also for what can happen when patient voice is built in from the start, not added at the end. Free. Multilingual. Valid information on lupus doi.org/10.1016/S266...

NEW RESEARCH—Development and validation of clinical criteria for the definition of disease activity in adult-onset Still's disease: a cohort study bit.ly/4rZwyKH Plus, linked Comment bit.ly/4dgPYHf #Medsky #Rheumsky

Early treatment for #RheumatoidArthritis leads to significant improvements in pain, fatigue, and quality of life – regardless of whether patients receive biologic drugs or conventional therapy. New KI study published in @thelancetrheum.bsky.social 🧪 #Rheumatology news.ki.se/early-initia...

Our April 2026 issue is live! This themed issue on patient and public involvement in rheumatology includes priority setting partnerships, study co-design, and co-production of self-management tools and care pathways, plus much more! thelancet.com/journals/lan... Cover by @emma-cheng.bsky.social

NEW RESEARCH—A treat-to-target strategy versus symptom-driven management of gout in the Netherlands (GO TEST Overture): a multicentre, open-label, pragmatic, superiority, randomised controlled trial bit.ly/4sYp5MO #Medsky #Rheumsky

NEW Correspondence—Effects of abatacept for those at high risk of rheumatoid arthritis @koraytascilar.bsky.social and colleagues report the long-term outcomes of individuals at risk of rheumatoid arthritis treated with abatacept or placebo in the ARIAA trial bit.ly/4lKYGQ3 #Medsky #Rheumsky

NEW RESEARCH—Ixekizumab in children with active psoriatic and enthesitis-related juvenile idiopathic arthritis: a multicentre, open-label, Bayesian trial including a randomised reference group to adalimumab bit.ly/4sDik2E Plus, linked Comment bit.ly/3P92Y7B #Medsky #Rheumsky

🍃March issue out now! New data on cardiac events in #COPD, septic shock, climate change and #TB, and much more 🔗 www.thelancet.com/issue/S2213-...

NEW VIEWPOINT—Paediatric rheumatology care in #Europe: setting children and adolescents into focus bit.ly/4cp7usm #Medsky #Rheumsky

Attending the World Congress on #SystemicSclerosis in Athens next week? Anna Clark, Editor-in-Chief, invites you to reach out with enquiries. Explore our scope, reach & impact, commitment to publishing excellence, & more: hubs.li/Q03BLchR0

Attending the #EuropeanLupusMeeting in Lisbon next week? Aisling O'Brien, Acting Deputy Editor, invites you to reach out with enquiries. Explore our scope, reach & impact, commitment to publishing excellence, & more: hubs.li/Q03BLchR0

🆕“The identification of distinct and non-guideline-concordant pathways highlights persistent gaps in primary care management of patients with osteoarthritis. These findings underscore the need for targeted primary care interventions to support... care before knee replacement.” ...

Our March 2026 issue is live! Including research in individuals at risk of developing arthritis, real-world data on anifrolumab in #SLE, #cardiovascular risk in #APS, and childhood-onset Sjögren's disease, plus much more! thelancet.com/journals/lan... #Rheumsky Cover by @emma-cheng.bsky.social

NEW RESEARCH—Recombinant herpes zoster vaccine in patients with autoimmune rheumatic diseases in Brazil: a double-blind, randomised, placebo-controlled, phase 4, non-inferiority study bit.ly/4bZ4dQe @uspoficial.bsky.social Plus linked Comment bit.ly/3MzdOD4 #Medsky #Rheumsky

NEWS—Frailty care in England deemed deficient bit.ly/4qFV16O #Medsky #Rheumsky

NEW podcast episode🎧 Acting Deputy Editor, Aisling O'Brien, talks to Fiona Pearce & Rachel Tattersall about #HLH mortality rates in Europe Listen now Apple: bit.ly/3Off8LR Spotify: bit.ly/3OFqGYM Full Article: bit.ly/4p5f9hT #Medsky #Rheumsky

🚀 Just launched – our new #goldopenaccess journal on medical imaging and theranostics! Learn more about the journal’s mission and explore related content from The Lancet Group today: hubs.li/Q041CgFF0 #medsky

NEW RESEARCH—Patient profiles and early response in patients with systemic #lupus erythematosus initiating #anifrolumab: interim analysis from the ongoing multicentre observational REVEAL study bit.ly/4aj9YWz Plus, linked Comment bit.ly/3ZliHT6 #Medsky #Rheumsky #SLE

Since their introduction 20 years ago, GLP-1 receptor agonists have revolu­tionised the treatment of diabetes and obesity. In our Feb editorial we discuss the current data on GLP-1 receptor agonists in rheumatic disease bit.ly/4c4N5Zi #Medsky #Rheumsky

NEW REVIEW—The path to interception in psoriatic disease: from conceptual clarity to clinical translation bit.ly/3ZD1NPE #Medsky #Rheumsky

Our Feb 2026 issue is live! Including total versus partial knee replacement, vagus nerve stimulation in hand #OA, mortality due to #HLH, #pregnancy outcomes in #vasculitis, plus much more! thelancet.com/journals/lan... #Medsky #Rheumsky Cover art by @emma-cheng.bsky.social

NEW RESEARCH—Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial bit.ly/4pSERqq Plus, linked Comment bit.ly/49v27Ga #Medsky #Rheumsky

NEW RESEARCH—Transcutaneous auricular vagus nerve stimulation versus sham stimulation in patients with erosive hand osteoarthritis (ESTIVAL): a randomised, multicentre, double-blind, sham-controlled trial bit.ly/4pKm4xD #Medsky #Rheumsky

NEW podcast episode🎧 Deputy Editor, Sophie Woolven, talks to John Isaacs & Josh Bennett about #sarcopenia and the RAMUS study, which looked at the skeletal muscle effects tofacitinib in #RA Apple: bit.ly/49fUy6d Spotify: bit.ly/3YSXxeC Full Article: bit.ly/45tQXPn #Medsky #Rheumsky